Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.

Adult Antibodies, Viral / blood COVID-19 Coronavirus Infections / epidemiology Cytokines / antagonists & inhibitors Female Humans Immune System Diseases / drug therapy Immunoglobulin G / blood Immunosuppressive Agents / administration & dosage Male Middle Aged Pandemics Pneumonia, Viral / epidemiology Prevalence Risk Seroconversion

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
24 07 2020

Historique:

received: 15 05 2020

accepted: 09 07 2020

entrez: 26 7 2020

pubmed: 28 7 2020

medline: 4 8 2020

Statut: epublish

Résumé

Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.

Identifiants

DOI: 10.1038/s41467-020-17703-6 PMID: 32709909 PMC: PMC7382482

pubmed: 32709909

doi: 10.1038/s41467-020-17703-6

pii: 10.1038/s41467-020-17703-6

pmc: PMC7382482

doi:

Substances chimiques

Antibodies, Viral 0

Cytokines 0

Immunoglobulin G 0

Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

3774

Subventions

Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)

ID : CRC1181

Pays : International

Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)

ID : Mascara

Pays : International

Références

Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).

doi: 10.1038/s41586-020-2008-3

Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

doi: 10.1016/S0140-6736(20)30183-5

Schett, G., Elewaut, D., McInnes, I. B., Dayer, J. M. & Neurath, M. F. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 19, 822–824 (2013).

doi: 10.1038/nm.3260

Pedersen, S. F. & Ho, Y. C. SARS-CoV-2: a storm is raging. J. Clin. Investig. 130, 2202–2205 (2020).

doi: 10.1172/JCI137647

Berlin, A. et al. The ageing joint-standard age- and sex-related values of bone erosions and osteophytes in the hand joints of healthy individuals. Osteoarthr. Cartil. 27, 1043–1047 (2019).

doi: 10.1016/j.joca.2019.01.019

Meyer, B., Drosten, C. & Müller, M. A. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 194, 175–183 (2014).

doi: 10.1016/j.virusres.2014.03.018

Petherick, A. Developing antibody tests for SARS-CoV-2. Lancet 395, 1101–1102 (2020).

doi: 10.1016/S0140-6736(20)30788-1

GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat. Commun. 11, 3436 (2020).

doi: 10.1038/s41467-020-17317-y

Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet https://doi.org/10.1016/S0140-6736(20)31304-0 (2020)

Coronavirus Disease 2019 (COVID-19). Daily Situation Report of the Robert Koch Institute 21/05/2020—Updated status for Germany. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-05-21-en.pdf?__blob=publicationFile (2020).

Tinsley, A. et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm. Bowel Dis. 25, 369–376 (2019).

doi: 10.1093/ibd/izy243

Winthrop, K. L. et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann. Rheum. Dis. 74, 2107–2116 (2015).

doi: 10.1136/annrheumdis-2015-207841

Blumentals, W. A., Arreglado, A., Napalkov, P. & Toovey, S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet. Disord. 13, 158 (2012).

doi: 10.1186/1471-2474-13-158

Zhang, B. et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front. Mol. Biosci. 7, 157 (2020).

doi: 10.3389/fmolb.2020.00157

Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis, https://doi.org/10.1093/cid/ciaa344 (2020).

Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003).

doi: 10.1016/S0140-6736(03)13412-5

Yoshikawa, T., Hill, T., Li, K., Peters, C. J. & Tseng, C. T. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol. 83, 3039–3048 (2009).

doi: 10.1128/JVI.01792-08

Luo, P. et al. Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol. 92, 814–818 (2020).

doi: 10.1002/jmv.25801

Rosenberg, E. S. et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann. Epidemiol. (2020) (in press).

Mansour, M. et al. Prevalence of SARS-CoV-2 antibodies among healthcare workers at a Tertiary Academic Hospital in New York City. J. Gen. Intern. Med., 1-2, https://doi.org/10.1007/s11606-020-05926-8 (2020).

An, P. et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. Lancet Gastroenterol. Hepatol. 5, 525–527 (2020).

doi: 10.1016/S2468-1253(20)30121-7

Norsa, L. et al. Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in Northern Italy. Gastroenterology, https://doi.org/10.1053/j.gastro.2020.03.062 (2020).

Monti, S. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 79, 667 (2020).

doi: 10.1136/annrheumdis-2020-217424

Haberman, R. et al. Covid-19 in Immune-mediated inflammatory diseases—case series from New York. N. Engl. J. Med., https://doi.org/10.1056/NEJMc2009567 (2020).

Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).

doi: 10.1038/s41591-020-0913-5

Barros, A. J. D. & Hirakata, V. N. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med. Res. Methodol. 3, 21 (2003).

doi: 10.1186/1471-2288-3-21